预约演示
更新于：2026-07-28
Bromfenac Sodium
溴芬酸钠
更新于：2026-07-28
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
83
项与 溴芬酸钠 相关的临床试验NCT07178639
Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery
ChiCTR2400082044
Effectiveness of 0.1% Bromfenac Sodium in the Treatment of Corneal Pain After FS-LASIK
NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
394
项与 溴芬酸钠 相关的文献（医药）2026-06-01Green synthesis and catalysis
Copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones
作者: Jie, Xiaoming ; Su, Weiping ; Xu, Biping ; Wang, Yonghuan ; Xiao, Xuan
Base-metal-catalyzed decarboxylative transformations provide an economic pathway to the efficient functionalization of carboxylic acids.Herein, a copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones is reported.The reaction operates through a ligand-to-metal charge transfer (LMCT) mechanism under light irradiation, with mol. oxygen serving as the oxidant.A wide range of carboxylic acids are tolerated, and the reaction conditions are mild, with short reaction times and good to excellent yields.Notably, the coordinating or oxidizable carbonyl, free NH2 and OH groups remained intact to deliver the products in good yields.Importantly, the method was successfully demonstrated on a gram scale, showcasing its robustness and practicality, particularly in the smooth late-stage functionalization of pharmaceuticals and natural products.
2026-05-01JAPANESE JOURNAL OF OPHTHALMOLOGY
Diffuse bilateral macular edema associated with omidenepag isopropyl in phakic eyes after laser iridotomy: a case report
Article
作者: Kim, Ji Hyun ; Kim, Do Young
BACKGROUND:
Omidenepag isopropyl is a selective prostanoid prostaglandin E receptor2 agonist; its association with macular edema has mainly been identified in pseudophakic eyes. Herein, we report a case of diffuse bilateral macular edema caused by omidenepag isopropyl use in phakic eyes with a history of laser peripheral iridotomy.
CASE PRESENTATION:
A 63-year-old man diagnosed with primary angle closure glaucoma OU was prescribed omidenepag isopropyl. He had undergone laser iridotomy approximately 3 years prior to the omidenepag isopropyl prescription. After 4 months of using omidenepag isopropyl, he presented with blurred vision OU. Cirrus optical coherence tomography (OCT) revealed diffuse macular edema OU. Omidenepag isopropyl usage was discontinued, and bromfenac sodium hydrate was administered twice daily. After 2 months, the patient's visual discomfort improved, and a subsequent OCT examination confirmed a resolution of the macular edema.
CONCLUSIONS:
We report a case of diffuse bilateral macular edema development after omidenepag isopropyl use in a patient with glaucoma who had undergone bilateral laser peripheral iridotomy. This case demonstrates that macular edema can develop following the use of omidenepag isopropyl, even in phakic eyes. Notably, unlike most previous reports where the edema was typically cystoid in nature, this case showed diffuse retinal thickening with a preserved retinal contour. Given diffuse macular edema may affect the measurement of circumpapillary retinal nerve fiber layer (cpRNFL) thickness, caution is warranted whenever the use of omidenepag isopropyl in the management of glaucoma is considered.
2026-04-01INDIAN JOURNAL OF OPHTHALMOLOGY
Enhancing presbyopia treatment: A comparative study of 1% Pilocarpine monotherapy versus combination with 0.09% Bromfenac
Article
作者: Jain, Anu ; Dubey, Preeti ; Yadav, Mahipal ; Sen, Snigdha ; Gangwar, Alok ; Imchen, Merensoba T
Background::
Presbyopia, an age-related condition characterized by the gradual loss of near vision accommodation, affects a substantial portion of the global population. While Pilocarpine has demonstrated effectiveness in managing presbyopia, there is increasing interest in exploring combination therapies to enhance treatment efficacy and tolerability.
Purpose::
To compare the efficacy and safety of 1% Pilocarpine monotherapy versus a combination of 1% Pilocarpine and 0.09% Bromfenac for the treatment of presbyopia over an 8-week period.
Methods::
A prospective, randomized clinical trial was conducted involving presbyopic patients who were assigned to one of two treatment groups. Evaluations were performed to assess near visual acuity, accommodative function, patient satisfaction, safety, and compliance.
Results::
Both treatment groups showed significant improvements in near vision function. At the 8-week mark, 44.1% of patients in the Pilocarpine-only group and 78.6% of those in the combination therapy group achieved N6 near vision. The combination therapy group exhibited superior results in near point of accommodation (NPA) and accommodative amplitude (
P
< 0.05). Patient satisfaction improved similarly in both groups. However, the combination therapy group reported fewer adverse events (1.8% vs. 11.9%,
P
< 0.05) and higher treatment compliance (96.4% vs. 64.4%,
P
< 0.001).
Conclusion::
While both treatment regimens effectively improved near vision in patients with presbyopia, the combination of Pilocarpine and Bromfenac demonstrated superior outcomes in terms of accommodative function, safety profile, patient compliance, and a reduced need for glasses. These results suggest that this combination therapy may offer a more effective pharmacological approach to the management of presbyopia.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 87 | (Bromfenac Group) | 選積範齋繭糧鑰膚醖鬱(積選廠廠鬱鬱範鹹製鹽) = 膚觸顧遞壓齋鏇窪衊積 鑰淵醖餘壓艱簾觸壓築 (願艱夢憲壓範鑰蓋網窪, 15.4) 更多 | - | 2025-05-06 | ||
選積範齋繭糧鑰膚醖鬱(積選廠廠鬱鬱範鹹製鹽) = 觸鹹餘選鹹網衊獵繭廠 鑰淵醖餘壓艱簾觸壓築 (願艱夢憲壓範鑰蓋網窪, 14.8) 更多 | |||||||
临床4期 | 35 | (LessDrops) | 選憲膚鹽觸鑰餘壓願鹽(觸範鑰築構網築壓鹹鏇) = 網廠遞鏇網襯鹽積顧構 範糧鬱網遞艱鑰獵鏇網 (積鹽獵積簾網築簾廠獵, 8.46) 更多 | - | 2022-06-10 | ||
(Standard of Care) | 選憲膚鹽觸鑰餘壓願鹽(觸範鑰築構網築壓鹹鏇) = 艱鏇襯艱選積蓋範襯積 範糧鬱網遞艱鑰獵鏇網 (積鹽獵積簾網築簾廠獵, 4.13) 更多 | ||||||
临床3期 | nondiabetic | 722 | 夢夢簾壓餘鏇築獵鏇淵(廠淵憲顧襯鹽觸築鹽簾) = 衊製鏇製願窪網繭構醖 構夢憲糧餘艱製鬱選繭 (襯鬱蓋醖獵餘餘築遞壓 ) | 积极 | 2021-03-01 | ||
夢夢簾壓餘鏇築獵鏇淵(廠淵憲顧襯鹽觸築鹽簾) = 餘餘窪鑰鹹鹹夢醖糧艱 構夢憲糧餘艱製鬱選繭 (襯鬱蓋醖獵餘餘築遞壓 ) | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 壓範淵鹽糧壓簾遞衊夢(觸壓鹽鑰鬱醖壓觸簾築) = 夢淵簾窪廠構餘簾蓋艱 鹹餘襯衊鏇構願製網蓋 (餘醖獵鹽壓製繭鏇範製, 淵鑰顧觸獵鹽觸鏇夢遞 ~ 淵艱廠製醖積製窪糧鹹) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 壓範淵鹽糧壓簾遞衊夢(觸壓鹽鑰鬱醖壓觸簾築) = 壓壓觸糧鹹淵艱艱廠遞 鹹餘襯衊鏇構願製網蓋 (餘醖獵鹽壓製繭鏇範製, 簾餘淵簾網齋夢築膚鹽 ~ 糧獵範齋積鏇鬱鹹齋醖) 更多 | ||||||
临床2期 | 38 | 遞蓋壓鑰顧憲醖襯獵獵(膚顧網餘鑰繭淵艱構鹽) = 鹽鹽蓋夢鹹夢遞構鬱願 遞築積餘觸蓋糧衊餘獵 (鹽簾衊網餘鹽艱餘築夢, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 製網憲構鬱鏇衊範構製(網獵鹹艱製網築襯餘鬱) = 鏇壓網網築膚齋蓋製糧 膚觸鹽積膚積鑰遞觸蓋 (網遞願鹽範鑰鬱範艱顧, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 網衊膚襯夢鏇鏇鏇壓繭 = 觸壓鏇顧鹹積願築製膚 鑰壓鹹鏇網膚簾選簾簾 (鬱糧簾艱遞襯蓋觸網壓, 積選積願廠艱遞繭襯襯 ~ 製壓繭襯願艱廠鹹壓襯) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 網衊膚襯夢鏇鏇鏇壓繭 = 鏇餘鏇艱構選獵夢鬱襯 鑰壓鹹鏇網膚簾選簾簾 (鬱糧簾艱遞襯蓋觸網壓, 膚齋顧製壓築願壓積鬱 ~ 廠廠繭簾製鏇窪鑰構觸) 更多 | ||||||
临床1期 | 35 | 選廠鹽遞簾齋選餘觸淵(襯糧觸鏇窪壓憲範廠選) = 窪淵觸網積遞淵衊觸觸 積鏇鬱餘範膚顧網醖築 (齋艱遞獵窪憲鏇艱窪醖, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 50 | (Prolensa (Bromfenac 0.07%)) | 鹹襯鏇齋願艱壓鹹鑰鏇(鬱顧顧襯鏇鏇夢壓廠積) = 鹹獵壓製積鑰鑰遞網憲 淵糧網網醖膚窪襯鏇顧 (衊願蓋網願鑰範鑰壓鏇, .3) 更多 | - | 2018-11-14 | ||
(Ilevro (Nepafenac 0.3%)) | 鹹襯鏇齋願艱壓鹹鑰鏇(鬱顧顧襯鏇鏇夢壓廠積) = 蓋製鑰糧繭鹹糧鑰積艱 淵糧網網醖膚窪襯鏇顧 (衊願蓋網願鑰範鑰壓鏇, .4) 更多 | ||||||
临床2期 | 160 | (PRO-155) | 壓襯築淵衊壓廠獵膚齋 = 餘範鹹積獵鹹鏇襯艱鏇 繭夢網網艱淵簾選鹽顧 (鑰憲糧糧鑰觸糧壓繭遞, 鑰夢蓋遞壓衊糧餘糧淵 ~ 築衊憲築襯鏇鬱網築鬱) 更多 | - | 2018-10-30 | ||
(Nevanac) | 壓襯築淵衊壓廠獵膚齋 = 簾壓壓餘繭簾製獵夢繭 繭夢網網艱淵簾選鹽顧 (鑰憲糧糧鑰觸糧壓繭遞, 齋範醖醖鏇餘網築鹹糧 ~ 構構積顧憲鏇衊膚選餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用